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Background: In primary esophageal cancer, studies have frequently focused on surgical
patients in an effort to link outcome to hospital- or surgeon-related experience, with operative
mortality used as the main outcome measure. Many studies have found an inverse relationship
between operative mortality and hospital volume and surgical expertise. This study aims to
assess the inﬂuence of surgeon-related expertise and hospital volume on the relative survival of
operated esophageal cancer patients.
Methods: From January 1994 to January 2002, a total of 1149 consecutive patients with
primary esophageal cancer were diagnosed in the region of the Comprehensive Cancer Center
North-Netherlands. As a proxy for surgeon-related expertise, hospitals in this region were
categorized into three types: university, teaching nonuniversity, and nonteaching hospitals.
The inﬂuence of hospital type on the relative survival of operated patients was studied by a
multivariate Poisson regression model.
Results: Of the 1149 patients, 18.5% underwent surgery. There was no evidence of selective
referral for surgery between the three hospital types with regard to age, tumor stage, and
location. For operated patients, the 5-year relative survival was 49.2% for the university
hospital versus 32.6% and 27.3% for teaching nonuniversity and nonteaching hospitals,
respectively (P = .0039). When adjusted for age, tumor stage, hospital volume and referral
frequency, the relative excess risk of death for the university hospital was considerably lower
at .57 (95% conﬁdence interval, .29–1.12) compared with nonteaching hospitals and .43 (95%
confidence interval, .24–.76) compared with teaching nonuniversity hospitals (P = .0126).
Conclusions: In our region, patients with esophageal cancer who underwent esophagectomy
in the university hospital had a markedly better relative survival compared with those who
underwent surgery at teaching nonuniversity and nonteaching hospitals, emphasizing the need
for referral of esophageal surgery to centers with a greater experience.
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With an incidence of 6.3 per 100,000 (European
standardized rate) in the period 1994–1998, esopha-
geal cancer ranked 13th among malignancies in men
and 12th in women in the Netherlands. Incidence
increased in both male and female patients, with an
estimated annual percentage change of 3.1% and
2.0%, respectively. The mortality for men and women
was, respectively, 9.4 per 100,000 and 3.1 per 100,000
in 2004, indicating that the prognosis of patients with
esophageal cancer remained poor in this period
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1678(http://www.kankerregistratie.nl). The only curative
option for esophageal cancer is surgery, which im-
plies that improving the outcome of surgery is the
best means of reducing mortality.
1
Esophageal cancer is one of the most challenging
pathological conditions confronting the surgeon. It
therefore seems reasonable to assume that concen-
tration of esophageal surgery could improve out-
come. Several studies have shown that various
characteristics, including surgeon subspecialty certi-
ﬁcation, hospital setting, and the number of proce-
dures performed, are associated with practice
variation, complication rates, and even outcome.
2–4
Evidence of improved outcome associated with spe-
cialist care exists for breast cancer,
2,4 ovarian can-
cer,
3,5 and malignant teratoma.
6 However, there is no
evidence of comparable quality for esophageal can-
cers. Several studies on esophageal cancer have fo-
cused on surgical patients in an effort to link outcome
to experience, either on the part of the institution or
the surgeon, by using postoperative mortality as the
main outcome measure.
7–9 A study on esophagecto-
mies performed in England during the late 1980s
found no independent association between operative
mortality and hospital surgical volume,
10 whereas
two North American studies did demonstrate a lower
mortality rate for esophagectomy when high-volume
and low-volume hospitals were compared.
11,12 Vari-
ous smaller studies also found lower operative mor-
tality rates among high-volume surgeons.
13,14
Few studies, if any, have attempted to relate
esophageal cancer patient survival to surgeon exper-
tise or hospital volume. To remedy this, in this study,
we assessed the eﬀect of surgeon-related expertise and
hospital volume on the relative survival of operated
esophageal cancer patients. We compared data from
university, teaching nonuniversity, and nonteaching
hospitals.
PATIENTS AND METHODS
Patients
All patients diagnosed with a primary invasive
esophageal cancer in the region of the Comprehensive
Cancer Centre North-Netherlands (CCCN) between
January 1994 and January 2002 were eligible for en-
try onto the study. Patients with a history of cancer
other than nonmelanoma skin cancer were excluded.
The patients were selected through the population-
based Regional Cancer Registry of the CCCN, which
covers the northern part of the Netherlands, a mainly
rural area with a population of approximately 2.1
million. The area is served by 17 community hospi-
tals, 3 of which are teaching hospitals and 1 of which
is a university hospital; the hospitals include four
radiotherapy departments and seven pathology lab-
oratories.
Data Collection by the Regional Cancer Registry
PALGA, a Dutch nationwide network and reg-
istry of histopathology and cytopathology, regularly
submits reports of all diagnosed malignancies to the
cancer registry. The national hospital discharge data
bank, which receives discharge diagnoses of admit-
ted patients from all hospitals, completes case
ascertainment. The cancer registry has no access to
death certiﬁcates. After notiﬁcation, trained registry
personnel collect data on diagnosis and staging
from the medical records, including pathology and
radiology reports, in the hospitals. The cancer reg-
istry collected all data regarding the diagnosis and
staging, but collected no data on speciﬁc surgical
treatment in this patient population before 2002.
The data collection occurs at least 4 months after
diagnosis to comprehensively document all aspects
of preoperative staging. All patients are staged
according to the tumor, node, metastasis system
(TNM) system for esophageal cancer in use during
that period.
15,16
In the Netherlands, the population registries of the
municipality contain information on the vital status
of their inhabitants. Vital status was established ei-
ther through information derived from the patients
medical records or through linkage of cancer registry
data with information from the population registries
of the municipality within the registry areas or
through linkage with the national death registry of
the Central Bureau of Genealogy. The regional can-
cer registry of the CCCN checked vital status by ac-
tive record linkage with municipal population
registries in 2002–2003 and 2005 and with the na-
tional death registry of the Central Bureau of Gene-
alogy in 2004.
Guidelines for Staging and Treatment
By establishing multidisciplinary teams and cancer
networks, the CCCN strives to improve the quality of
cancer care. Within the CCCN area tumor working
groups, comprising delegated specialists representing
all regional hospitals, that have been developing and
revising guidelines on diagnosis and treatment. The
regional guidelines for esophageal cancer were based
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the International Union Against Cancer in use at that
time.
Statistics and Deﬁnitions of Variables
The v
2 test was used to compare the distribution
over the patient population for categorical variables.
For continuous variables, analysis of variance was
used. Relative survival analysis was performed to
estimate the effect of university, teaching nonuni-
versity, and nonteaching hospitals on the prognosis
of operated patients with esophageal cancer. The
a priori hypothesis was that patient volume and
hospital expertise would increase from nonteaching
to university teaching hospitals. Survival time was
calculated from the date of diagnosis and ended at
the date of death, including perioperative death, or
the date of most recent linkage with the municipal
population registries and/or national death registry.
The overall survival probability was estimated by the
Kaplan-Meier method.
The expected survival probability was calculated
by using age-, sex-, and period-matched mortality
rates that were based on life expectancy tables in the
Netherlands (http://www.statline.cbs.nl/StatWeb/)
and was estimated by the Ederer 2 method.
17 The
cumulative relative survival (the ratio of the overall
survival to the expected survival) was estimated by
Stata (version 8.0) software and the strs function. The
relative survival, which estimates the net esophageal
cancer survival in the hypothetical situation that
esophageal cancer is the only possible cause of death,
has been shown to be a good estimator of disease-
speciﬁc survival in the absence of information on the
cause of death or in case information on the cause of
death is inaccurate.
The excess mortality rate was calculated by sub-
tracting the expected number of deaths, estimated
from the expected survival probability, from the ob-
served number of deaths in a subgroup or stratum
and dividing the resulting excess number of deaths by
the number of accumulated person-years, taking
censoring into account. The relative excess risks
(RER) of death were estimated as the ratio of excess
mortality rates. RERs were estimated by a multi-
variate generalized linear model with a Poisson error
structure, which was based on collapsed relative
survival data, by using exact survival times.
18 By use
of this model, the effect of the type of hospital (uni-
versity, teaching nonuniversity, and nonteaching) was
studied, adjusting for the effect of various covariables
on the excess mortality experienced by our cohort.
Variables included in the ﬁnal model were age
(<50, 50–59, 60–69, >70), stage based on collapsed
TNM data (stage 1,2a, 2b, 3/4, unknown), hospital
volume (<20 patients operated, ‡20 patients oper-
ated), frequency of referral (high referral [>33.3%],
low referral [£33.3%]), and time since diagnosis
(1-year intervals). The pathological stage was used
whenever possible; in the absence of information
about the pathological stage, the clinical stage was
used.
RESULTS
In the period 1994–2002, a total of 1149 patients
were diagnosed with esophageal cancer, comprising
796 men and 353 (69.3%) women (30.7%). The
median age was 68 years (range, 17–103 years). Pa-
tient characteristics are described in Table 1. A large
proportion of the patients was diagnosed at an ad-
vanced stage of disease; 45.5% were stage III or
higher. A further 28.8% were insufﬁciently staged. Of
the 1149 patients, 85 patients (7.4%) were initially
diagnosed in the university hospital, 428 patients
(37.2%) in teaching nonuniversity hospitals. The
remaining 636 patients (55.4%) were diagnosed in the
nonteaching hospitals. Patients who were referred
from the hospital of initial diagnosis for treatment
may have subsequently undergone further diagnostic
testing, and previously performed tests determined to
be insufﬁcient were repeated. The 5-year relative
survival rate for men with esophageal cancer was
12.8% vs. 9.8% for women (P = .496). The 5-year
relative survival markedly decreased as the stage ad-
vanced. The 5-year relative survival was 71.5% in
stage I, 26.5% in stage IIA, 13.3% in stage IIB, 9.2%
in stage III, 1.3% in stage IV, and 6.7% for patients
with unknown stage (P < .0001).
As Table 1 shows, only 213 patients (18.5%)
underwent surgery. Older age (P < .001), advanced or
unknown stage (P < .001), and proximal tumor
location (P < .001) resulted in a lower probability of
tumor resection. Squamous cell carcinoma was also
associated with less surgery, but it was highly corre-
lated with the tumor location. In all, 21.4% of the pa-
tients diagnosed in nonteaching hospitals underwent
surgery, compared with 15.9% and 10.6% for teaching
nonuniversity and university hospitals, respectively
(P = .011). Adjusted for age, stage, and tumor loca-
tion, the odds of operation was 1.89 (95% conﬁdence
interval [95% CI], 1.26–2.82) for patients diagnosed
in a nonteaching hospital compared with patients
diagnosed in a teaching nonuniversity hospital.
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surgery after diagnosis in the hospital of presentation
(Table 2). The nonteaching hospitals referred 57.4%
of patients diagnosed in their hospitals for an oper-
ation elsewhere. Of the 14 nonteaching hospitals in
which esophageal cancer patients were diagnosed, 12
referred nearly all (75%–100%) patients, and two
rarely (.0%–6.9%) referred patients. The teaching
nonuniversity hospitals referred 26.5% of the patients
diagnosed in their hospitals to a larger institution for
TABLE 1. Characteristics of operated and nonoperated patients with esophageal cancer diagnosed 1994–2002
Characteristic
Total Operated Nonoperated
P value N % n % n %
Sex .465
Male 796 69.1 152 71.4 644 68.6
Female 353 30.9 61 28.6 292 31.2
Histology <.001
Squamous cell carcinoma 415 36.1 62 29.1 353 37.7
Adenocarcinoma 592 51.6 140 65.7 453 48.4
Other 141 12.3 11 5.2 130 13.9
Tumor location <.001
Upper thoracic 82 7.1 3 1.4 79 8.4
Middle thoracic 210 18.3 36 16.9 174 18.6
Lower thoracic 770 67.0 169 79.3 601 64.2
Overlapping and unspeciﬁed 87 7.6 5 2.3 82 8.8
Age at diagnosis (y) <.001
<50 86 7.5 24 11.3 62 6.6
50–59 221 19.2 67 31.5 154 16.5
60–69 319 27.8 80 37.6 239 25.5
70+ 523 45.5 42 19.7 481 51.4
Stage <.001
1 52 4.5 32 15.0 20 2.1
2A 174 15.1 65 30.5 109 11.7
2B 69 6.0 26 12.2 43 4.6
3 207 18.0 74 34.7 133 14.2
4 316 27.5 8 3.8 308 32.9
Unknown 331 28.8 8 3.8 323 34.5
Total 1149 100.0 213 100.0 935 100.0
TABLE 2. Referral pattern for esophageal cancer surgery per hospital in the North-Netherlands, 1994–2002
Hospital Operated in hospital of diagnosis, n (%) Referred for surgery, n (%) Total (n)
High-referral nonteaching hospitals 20 (20.8) 76 (79.2) 96
Hospital A – 2 (100.0) 2
Hospital B – 3 (100.0) 3
Hospital C – 3 (100.0) 3
Hospital D – 9 (100.0) 9
Hospital E 2 (11.8) 15 (88.2) 17
Hospital F 1 (14.3) 6 (85.7) 7
Hospital G 3 (18.8) 13 (81.3) 16
Hospital H 3(25.0) 9 (75.0) 12
Hospital I 3 (30.0) 7 (70.0) 10
Hospital J 1 (33.3) 2 (66.7) 3
Hospital K 1 (33.3) 2 (66.7) 3
Hospital L 6 (54.5) 5 (45.5) 11
Low-referral nonteaching hospitals 38 (95.0) 2 (5.0) 40
Hospital M 27 (93.1) 2 (6.9) 29
Hospital N 11 (100.0) – 11
High-referral teaching, nonuniversity hospitals 7 (36.8) 12 (63.2) 19
Hospital O 7 (36.8) 12 (63.2) 19
Low-referral teaching, nonuniversity hospitals 43 (87.8) 6 (12.2) 49
Hospital P 24 (82.8) 5 (17.2) 29
Hospital Q 19 (95.0) 1 (5.0) 20
Low-referral university hospital 9 (100.0) – 9
Hospital R 9 (100.0) – 9
117 (54.9) 96 (45.1) 213
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patients.
Table 3 compares characteristics of the operated
patients in the three hospital types. Of the 213 oper-
ated patients, 95 underwent surgery in the university
hospital; 86 of these patients were referrals. The three
teaching nonuniversity hospitals provided surgery to
60 patients, including 10 referrals: one hospital per-
formed surgery on 7 patients, with the two other
hospitals operating on more than 20. The remaining
58 patients underwent surgery at one of the 14 non-
teaching hospital after all were initially diagnosed in
the same hospital; two low-referral hospitals operated
on more than 10 patients, eight hospitals operated on
5 or fewer patients, and the remaining four high-
referral hospitals did not perform any esophageal
cancer surgery. There were no statistically signiﬁcant
differences in the distribution of age (P = .230), stage
(P = .299), or tumor location (P = .130) between the
hospital types, again showing little evidence of
selective referral. However, of all operated patients
per hospital, a slightly larger proportion of stage III/
IV tumors were operated on in the nonteaching
(46.6%) and university hospitals (41.1%) compared
with the teaching nonuniversity hospitals (26.7%),
and the portion of stage IIA tumors was somewhat
higher in nonteaching (31.0%) and teaching nonuni-
versity hospitals (38.3%) compared with the univer-
sity hospital (25.3%).
The cumulative relative survival for university,
teaching nonuniversity, and nonteaching hospitals is
shown in Fig. 1. Surprisingly, relative survival was
markedly better in the university hospital compared
with teaching nonuniversity and nonteaching hospi-
tals. The 5-year relative survival was 49.2% for the
university hospital versus 32.6% and 27.3% for
teaching nonuniversity and nonteaching hospitals,
respectively (P = .0039, Table 4). In univariate
analysis, the RER for university and teaching non-
university was, respectively, .48 (95% CI, .30–.74) and
TABLE 3. Characteristics for operated esophageal cancer patients diagnosed 1994–2002, according to hospital of surgery
Characteristic
Total
Teaching,
nonuniversity University Nonteaching
P value N % n % n % n %
Stage
Stage 1 32 15.5 12 20.0 14 14.7 6 10.3 .299
a
Stage 2A 65 26.8 18 38.3 23 25.3 24 31.0
Stage 2B 26 12.2 8 13.3 12 12.6 6 10.3
Stage 3 + 4 82 38.5 16 26.7 39 41.1 27 46.6
Unknown 8 7.0 1 1.7 6 6.3 1 1.7
Age at diagnosis (y)
<50 24 11.3 8 13.3 13 13.7 3 5.2 .230
50–59 67 31.5 16 26.7 36 37.9 15 25.9
60–69 80 37.6 25 41.7 30 31.6 25 43.1
70+ 42 19.7 11 18.3 16 16.8 15 25.9
Histology
Squamous cell carcinoma 62 29.1 21 35.0 27 28.4 14 24.1 .606
Adenocarcinoma 140 65.7 35 58.3 63 66.3 42 72.4
Other 11 5.2 4 6.7 5 5.3 2 3.4
Tumor location
Upper and middle thoracic 39 18.3 13 21.7 17 17.9 9 15.5 .130
Lower thoracic 169 79.3 47 78.3 73 76.8 49 84.5
Not stated 5 2.3 – – 5 5.3 – –
Total 213 100.0 60 100.0 95 100.0 58 100.0
a Excluding stage unknown.
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FIG. 1. Cumulative relative survival of patients operated for
esophageal cancer diagnosed during 1994–2002 according to hos-
pital type.
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hospitals. The proportion of operated patients who
died within 3 months after diagnosis differed between
university, teaching nonuniversity and nonteaching
hospitals (4.2%,1 3 . 3 % and 19.0% respectively, P =
.013). Excluding patients who died within the ﬁrst 3
months, the RER for university and teaching non-
university was, respectively, .59 (95% CI, .35–1.00)
and .97 (95% CI, .56–1.69) compared with non-
teaching hospitals.
In a multivariate analysis to adjust for the prog-
nostic eﬀect of patient age, tumor stage, tumor
location, hospital volume, frequency of referral, and
time since diagnosis, we found that stage, age, hos-
pital type, and time since diagnosis were indepen-
dently associated with the RER (Table 4). The RER
increased with more advanced stage. Patients aged
<50 and patients aged ‡70 had a lower RER com-
pared with patients aged 50–69 years. Adjusted for
age, stage, and time since diagnosis, the RER for the
university hospital was still considerably lower, at .57
(95% CI, .29–1.12), compared with nonteaching
hospitals and .43 (95% CI, .24–.76) compared with
teaching nonuniversity hospitals (P = .0126). There
was some evidence in the data for an independent
effect of hospital volume, with a lower RER (.62;
95% CI, .34–1.12) if a hospital operated on ‡20 pa-
tients during the study period.
In our study 8.9% of the operated patients received
some form of adjuvant therapy (Table 5). Of these
patients, 6.1% received preoperative chemotherapy
and 2.8% received postoperative radiotherapy. Pa-
tients receiving chemotherapy were all treated in the
university hospital. Comparing clinical and patho-
logical stage, we found no evidence that chemother-
apy led to a marked downstaging.
DISCUSSION
Our study shows that patients who underwent
surgery for esophageal cancer in the university hos-
pital had a markedly better relative survival, with a
50% lower risk of death compared with patients
treated in nonuniversity hospitals. The risk of death
did not diﬀer for patients operated in teaching non-
university or nonteaching hospitals. In our study, we
found that a higher hospital volume was weakly
associated with better survival. Although hospital
volume seems to inﬂuence better survival, it is un-
likely that the diﬀerence between the three hospital
types can be completely explained by hospital vol-
ume; other factors likely play a role. A recent British
study found no eﬀect of hospital volume on survival
for the operated patients; further, this study did not
ﬁnd teaching hospital status independently associated
TABLE 4. Overall and relative 5-year survival and estimated excess risk (RER) of death with 95% conﬁdence intervals (95%
CI) for operated esophageal cancer patients diagnosed 1994–2002
Characteristic N OS (5 y) RS (5 y) OD (5 y)
Univariate Multivariate
95% CI P value ED (5 y) RER
a 95% CI RER
a
Stage <.0001
Stage 1 32 87.5% 99.1% 4 3.1 .06 .01–.32 .05 .01–.22
Stage 2A 65 46.1% 52.4% 33 3.9 .44 .27–.70 .39 .24–.63
Stage 2B 26 21.8% 24.7% 19 1.1 .75 .43–1.29 .72 .40–1.27
Stage 3+4 (reference) 82 14.2% 14.5% 65 1.6 1.00 1.00
Unknown 8 16.7% 18.0% 6 .2 .99 .41–2.35 1.62 .65–4.01
Hospital type .0126
Nonteaching (reference) 58 24.9% 27.3% 40 2.3 1.00 1.00
Teaching nonuniversity 60 29.7% 32.6% 39 1.9 .89 .55–1.42 1.32 .79–2.22
University 95 44.3% 49.2% 48 5.6 .48 .30–.77 .57 .29–1.12
Age (y) .0467
<50 (reference) 24 47.6% 48.6% 11 .2 1.00 1.00
50–59 67 32.1% 33.6% 42 1.2 1.73 .87–3.44 1.51 .74–3.04
60–69 80 30.9% 35.1% 52 3.5 2.12 1.07–4.18 2.36 1.18–4.70
70+ 42 41.9% 54.5% 22 4.9 1.42 .64–3.14 2.05 .94–4.46
Hospital volume .1125
<20 patients operated 38 19.0% 22.3% 27 1.3 1.00 1.00
‡20 patients operated 175 37.8% 41.7% 100 8.5 .53 .33–.83 .62 .34–1.12
Referral rate .8080
High (>33.3%) 115 35.4% 39.2% 66 5.2 1.00 1.00
Low (£ 33.3%) 98 34.1% 37.8% 61 4.6 1.16 .79–1.69 .94 .57–1.54
OS, overall survival; RS, relative survival; OD, observed deaths; ED, expected deaths.
a Adjusted for time since diagnosis.
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operated patients or the population as a whole.
10
Our study is one of the ﬁrst studies to research the
eﬀect of a marker for hospital/surgeon experience on
patient survival. Most studies to date have evaluated
30-day postoperative or in-hospital mortality, and
several demonstrated an inverse relationship between
volume or surgical experience and operative mortal-
ity after esophageal resection.
8,11,19 A Dutch study
found that hospitals performing 1 to 10 operations
per year for esophageal cancer and cancer of the
gastroesophageal junction had an operative mortality
of 12.2%, compared with 4.9% for hospitals per-
forming >50 procedures per year.
19 An American
study had a similar result, with a mortality of 3.0%
among high-volume hospitals and 12.2% among low-
volume hospitals for both distal and proximal
esophageal cancer,
12 but this study used a cutoff
point of ﬁve procedures per year to differentiate be-
tween high- and low-volume hospitals. What thresh-
old distinguishes high-volume from low-volume
hospitals remains matter of discussion. The results of
these studies do suggest that centralization of
esophageal surgery, so that only a few hospitals per
region operate on esophageal cancer patients, may
improve survival. The results of our study support
the recommendation for referral of esophageal cancer
patients to a center where there is a speciﬁc focus on
esophageal cancer treatment. Combined with the fact
that the surgical literature is increasingly advocating
the need for centralization, we think that further
research into the advantages of centralization of
esophageal cancer treatment is warranted.
One of the possible pitfalls in our study remains
selective referral. We showed that the likelihood of
being operated on was 47% higher for patients diag-
nosed in a nonteaching hospital than for those diag-
nosed in teaching nonuniversity hospitals. Adjusted
for age, stage, and tumor location, this was even
higher, 73%, indicating that nonteaching hospitals
considered patients with a worse prognosis possible
candidates for surgery, or at least for referral to
evaluate resectability. However, adding hospital
referral frequency to our multivariate analyses
showed no inﬂuence of referral on overall and relative
survival or RER. The referral pattern showed little
evidence for selective referral. Those nonteaching
hospitals that referred patients referred almost all,
and the teaching nonuniversity hospitals referred
only few patients for surgery (Table 2). The referral
pattern of the nonteaching hospitals implies that the
university hospital operated on a priori prognosti-
cally worse patients. This is a likely explanation for
the higher number of stage III patients in the uni-
versity hospital.
To minimize the eventual eﬀect of any residual
selection referral, the relative survival rate was ad-
justed for case mix, despite there being no statistically
signiﬁcant diﬀerences in the distribution of age, stage,
and sex between the diﬀerent types of hospital.
One may suggest that patients who underwent
esophagectomy in the university hospital were mostly
referred for treatment, thus adding a delay before
surgery. A consequence could be that these patients
had thus a slightly longer preoperative survival time,
estimated to be between 2 and 4 weeks in our study.
This short delay could mean that prognostically
worse patients scheduled for surgery eventually fall
out of the surgery category through disease progres-
sion during the delay period. However, little is known
in the literature about the eﬀect of longer preopera-
tive delays on surgical outcome or eligibility in
esophageal cancer. Although patients with advanced
disease may miss surgery through stage progression,
patients who do end up having surgery also progress,
meaning the university hospital operates on patients
with more advanced disease. This should negatively
inﬂuence the survival outcome and would not explain
the better performance by the university hospital.
Furthermore, even if we were very conservative and
excluded all patients who died in the ﬁrst 3 months of
our study, the university hospital still performs far
TABLE 5. Adjuvant therapies for patients operated for esophageal cancer diagnosed 1994–2002, according to hospital of
treatment
Treatment
Nonteaching
Teaching,
nonuniversity University Total
n % n % N % N %
Surgery 57 98.3 58 96.7 79 83.2 194 91.1
Surgery + radiotherapy 1 1.7 – – 5 5.3 6 2.8
Surgery + chemotherapy – – 2 3.3 11 11.6 13 6.1
Total 58 100.0 60 100.0 95 100.0 213 100.0
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hospitals. So although we cannot discount early
mortality as a factor in survival, we think that it is
unlikely that the diﬀerence in performance can be
fully explained by this.
We had no information about the operative pro-
cedure that had been performed. Treatment guide-
lines indicated a curative surgical approach for
tumors encompassing £5 cm of the length of the
esophagus, as based on ultrasonographic or radio-
logical examination. Surgical resection could be at-
tempted for tumors 5–8 cm in length. For this last
group, neoadjuvant chemotherapy, which was pro-
vided in the university hospital after proof of locally
advanced disease, could be attempted to improve
resectability. For adenocarcinomas, a transthoraco-
abdominal approach with two-field lymphadenecto-
my was advised, combining a midline laparotomy
and a right-sided thoracotomy. Alternatively a tran-
shiatal blind esophagectomy could be performed with
a cervical esophagogastrostomy. For distal adeno-
carcinomas without Barrett dysplasia, a left-sided
thoracotomy with intrathoracic anastomosis was an
alternative approach.
In general, patients in our population who were
operated on in the university hospital underwent a
transthoracic esophagectomy, with the exception of
superﬁcial T1 tumors, whereas patients treated in
regional hospitals frequently underwent surgery with
a transhiatal approach. Therefore, the two main
operative strategies we encountered were transhiatal
resection and transthoracoabdominal resection with
a two-ﬁeld lymph node dissection. There is no evi-
dence in literature that the outcome diﬀers for these
two procedures,
14,20 except for a tendency toward an
improved long-term survival in the extended trans-
thoracic group in the study of Hulscher et al.
21 So the
clinical outcome in our population is likely uninﬂu-
enced by differences in surgical procedure. However,
there is possibly a stage migration effect between the
more thorough pathological staging in operations
with lymphadenectomy, as in the university hospital,
and understaging in patients undergoing a transhiatal
esophageal resection.
A few of the operated patients received neoadju-
vant therapy in our study, mostly in the university
setting, which might account for a small part of the
better survival in the university hospital. Separate
analysis, however, showed that patients in our study,
who received neoadjuvant therapy with surgical re-
moval of the tumor, did not perform better than
patients who underwent surgical removal alone in the
university hospital. In other studies, the preoperative
eﬀect of cisplatin-based chemotherapy on both ade-
nocarcinoma and squamous cell carcinoma showed
no increase in overall survival.
22–25 Preoperative
chemotherapy or radiotherapy can result in down-
staging and thus lead to a better resectability, but no
clear downstaging was seen in our study when com-
paring pre- and postoperative clinical and patholog-
ical stage. In several randomized, controlled studies,
postoperative radiotherapy demonstrated either no
increase
26,27 or a decrease
28 in survival compared
with resection alone. Postoperative chemotherapy
has also been compared with surgical management
alone in several randomized controlled trials, without
demonstrating an improvement in survival.
29
According to these results, the effect of perioperative
treatment is not likely to inﬂuence our data.
We found a tentative relationship between higher
volume and a better relative survival. However, this
issue still is a debatable problem in determining
treatment guidelines. Therefore, we suggest that
guidelines concerning speciﬁc referral of esophageal
cancer patients should be based on hospital out-
comes, preferably in experienced centers, rather than
on annual numbers of procedures as long as the
factor that is determining patient survival is still un-
known.
The individual surgeon could be an important
parameter in determining the hospital outcome. Al-
though the implications of the assertion that some
surgeons have better outcomes than others make
clinicians uncomfortable, there should be little doubt
that it is true. Variation in performance has been
shown to be related to surgeon characteristics,
including surgical volume, subspecialization, and the
hospital setting in which they operate.
7,30 Individual
surgical experience has been associated with the
postoperative mortality of esophageal cancer. Sutton
et al.
9 showed a reduction in mortality from 6% to 3%
after 150 procedures. Miller et al.
14 published results
in one center demonstrating an operative mortality of
22% among esophageal resections performed by a
surgeon who performed fewer than six procedures a
year. These results are widely quoted in the surgical
literature as proving that surgeons without the nec-
essary expertise should not perform esophageal
resections.
There is some evidence that subspecialization
improves outcomes. Herr et al.
31 found that pa-
tients who underwent radical cystectomy by urology
oncologists had substantially lower rates of local
tumor recurrence than those who were operated on
by general urologists (6% vs. 23% (P = .006).
Dueck et al.
32 reported that patients who under-
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aneurysm had markedly better outcomes when the
surgery was performed by a vascular surgeon rather
than a general surgeon. The effect of subspecial-
ization of the surgeon on the outcome of esopha-
geal cancer has not yet been studied, but it may be
a promising factor for decisions with regard to
centralization.
It has been suggested in previous reports that the
skill of the anesthesia and nursing staﬀ aﬀects mor-
bidity and relative survival of esophagectomy pa-
tients and that it confounds the surgeons personal
outcome.
7,9 Better critical-care experience of the
support staff may explain a higher relative survival in
university hospitals; staff may be more adept at car-
ing for esophagectomy patients. Some authors have
suggested that the expertise of the anesthesia and
nurses in a hospital is directly correlated to the hos-
pital and surgical load in that hospital.
9 However,
expertise can be acquired elsewhere, and expertise
only develops through effective feedback, not only by
number of patients.
Although referral to dedicated centers possibly
results in improved relative survival, the focus entails
some disadvantages, which should be considered.
Referral to centers means that many patients have to
travel to distant sites, which can create hardship for
the patient and his or her family. In-hospital family
support and postoperative follow-up are more diﬃ-
cult when the hospital is farther away. Finlayson
et al.
33 demonstrated that 45% of the patients prefer
to stay in their local area even if the projected oper-
ative mortality is doubled. However, that study rep-
resents the American situation, and it is questionable
whether distance is perceived to be a problem in the
Dutch situation. In our region, which has a relatively
high density of hospitals, a recent patient survey
showed that traveling distance was not considered a
critical issue.
In conclusion, we demonstrated that in our region,
the relative survival for patients operated on for
esophageal cancer is better in the university hospital
compared with teaching nonuniversity and non-
teaching hospitals, emphasizing the need for referral
to centers focused on the treatment of esophageal
cancer. The underlying parameter for the observed
diﬀerence remains unclear. We suggest that centers at
least periodically review the morbidity and mortality
rates of esophageal resections to assess their outcome
and the possibility of referral. Eligibility for centers
focused on esophageal cancer treatment should
therefore be based on patient outcomes rather than
on patient numbers.
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